Penwest Pharmaceuticals Co. (PPCO) – Buzz Stock of the Day

Posted on Tuesday, June 8th, 2010

Shares of drug maker, Penwest Pharmaceuticals Co. (Nasdaq: PPCO) were up as much as 21 percent in morning trading on Tuesday after the company announced that it settled a patent litigation with Impax Laboratories, Inc. (Nasdaq: IPXL) over the production and sale of a generic version of the pain drug Opana, which is jointly developed by Penwest and Endo Pharmaceuticals Holdings, Inc. (Nasdaq: ENDP).

Penwest shares rose as high as $3.38, up from Monday’s closing price of $2.78 per share.

[–quote–]

Penwest and Endo have agreed to grant Impax a license to sell the copycat on Jan. 1, 2013. Impax will have 180 days of marketing exclusivity for 5 mg, 10 mg, 20 mg, 30 mg and 40 mg tablets of the drug, Reuters reported. Impax could also get up to $40 million in milestones from Endo for an Impax brand drug the two companies will promoted together outside the field of neurology. Further terms of the settlement were not disclosed.

Endo and Penwest also settled a similar patent litigation with Sandoz Inc, a unit of Swiss drugmaker Novartis AG (NOVN.VX), granting Sandoz a license to sell the generic of the drug on Sept. 15, 2012.

Tags: , , , , , ,
Posted in Health Care Stocks by admin | No Comments »


Celgene Corp. (CELG) – Buzz Stock of the Day

Posted on Monday, June 7th, 2010

Shares of cancer drug maker, Celgene Corp. were up 6 percent from Friday’s close after the company announced positive results from a Phase II study of lenalidomide (REVLIMID) in untreated patients with chronic lymphocytic leukemia at the annual meeting of the American Society of Clinical Oncology (ASCO).

Results of the Phase II single-arm study reported that at a median follow-up of 23 months, the overall response rate (OR) for 60 evaluable patients was 62 percent, and 15 percent of patients achieved a complete response (CR/CRi). At the median follow-up, median progression-free survival had not been reached and the overall survival rate was 90 percent. The most common grade 3 or 4 adverse events reported in the study were neutropenia (38 percent of cycles), thrombocytopenia (14 percent of cycles), and anemia (<1 percent of cycles). Grade 3-4 infections were observed in 15 percent of patients.

[–quote–]

REVLIMID is an IMiDs® compound, which along with other IMiDs continue to be evaluated in over 100 clinical trials. The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, including composition-of- matter and use patents. REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in nearly 50 countries, encompassing Europe, the Americas, the Middle-East and Asia, and in combination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.

Shares of Celgene Corp. are up 20 percent over the past 12 months.

Tags: , , , , , ,
Posted in Health Care Stocks by Sheryl | No Comments »


Belltower Entertainment Corp. (BTOW) – Penny Buzz Stock of the Day

Posted on Monday, June 7th, 2010

Shares of Belltower Entertainment Corp. (OTCBB: BTOW) were up more than 30 percent today on heavy volume after the company announced its intent to begin producing direct response commercials.

Potential revenue sources for the company will include production fees from the commercials and back end profit participation in the products being marketed to the public through the television commercials the company produces.

[–quote–]

Last week, the company announced that it has attached director, Michael D. Olmos (Splinter), and Academy Award Winner Forest Whitaker to star in, and serve as the executive producer for Belltower Entertainment’s feature film entitled “Little Treasure,” which tells the story of an American, bi-racial couple. The film will be shot entirely on location in Shanghai. Belltower Entertainment Corp. used a portion of a $1 million credit facility to secure Whitaker and Olmos through William Morris Endeavour Agency (WME) where they are both repped.

Belltower will retain copyright ownership of the film, and will have majority control over production, financing and distribution.

Tags: , , ,
Posted in Consumer Discretionary Stocks by admin | No Comments »


Penny Buzz Stocks – LNG, SECI, UCHC

Posted on Friday, June 4th, 2010

Here are 3 penny stocks to add to your watch list today:

Cheniere Energy, Inc. (AMEX:LNG): Shares up after the company announced plans to export U.S. natural gas overseas from its Sabine Pass terminal in Louisiana in a strategy shift prompted by large increases in U.S. natural gas production.

Sector 10, Inc. (OTCBB: SECI): Up 30 percent on high volume after the company announced the upcoming release of the PLX-3D integration software package and its integrated components as an easy to use mobile application for the iPhone and iPad produced by Apple.

Uni Core Holdings Corp. (OTCBB: UCHC): Up 32 percent today on decent volume. Recent developments include a new research report from Skymark Research, and plans to close the acquisition of APT Paper Group, which includes FG Management Company Limited, Global Golden Group Investments Co., Ltd., Wise Link Management Ltd., Plan Star Development Limited, and Sure Strong Limited. Uni Core Holdings Corp. is an ‘incubator’ of mid- to large-size companies in China.

Tags: , , , , ,
Posted in Energy Stocks, Industrial Stocks, Materials Stocks, Penny Stocks, Technology Stocks by Sheryl | 1 Comment »


Martek Biosciences Corp. (MATK) – Buzz Stock of the Day

Posted on Friday, June 4th, 2010

Shares of infant formula and dietary supplements maker Martek Biosciences Corp. (Nasdaq: MATK) were up as much as 18 percent from Thursday’s close, after the company announced a 14 percent increase in second quarter earnings driven by its recent acquisition of Amerifit Brands.

For the quarter ended April 30, Martek earned $12.6 million, or 37 cents per share, up from $11 million, or 33 cents per share, during the same period a year prior. Excluding charges, the company said it would have earned 45 cents per share. Revenue for the quarter was up 34 percent to $124 million from $92.4 million a year ago.

Analysts polled by Thomson Reuters  expected net income of 32 cents per share on revenue of $114.9 million.

Martek completed its $200 million buyout of Amerifit Brands in February. Branded consumer health products from the Amerifit buyout added $18 million to revenue. Sales from the company’s infant formula business rose 12 percent to $86.3 million while sales in Martek’s food and beverage business were up 52 percent to $4.5 million. Sales of products in its pregnancy and nursing, nutritional supplements and animal feeds business grew by 30 percent to $8.8 million.

[–quote–]

Martek Biosciences expects third-quarter net income between 33 cents and 36 cents per share on revenue between $113 million and $118 million. Analysts have forecast net income of 39 cents per share on $112.6 million in revenue, on average. For the full fiscal year, the company expects revenue between $440 million and $445 million — which tops analysts’ average $439.1 million estimate.

“The improving economy, new launches of products with Martek’s life’sDHA, growing international markets for Martek’s products and sales of Amerifit’s branded consumer health products all contributed to Martek’s record quarterly results,” said Martek’s CEO, Steve Dublin in a statement. “This year as a whole is looking strong from a revenue perspective, although revenues for the balance of 2010 are projected to be somewhat uneven on a quarter-to-quarter basis due to customer plant shutdowns for maintenance and other timing matters. Martek’s strong run rate coming out of fiscal 2010 should provide an excellent platform from which to grow as some of Martek’s new products currently in development begin to hit the market over the next eighteen months as additional consumer brands launched through Amerifit’s marketing and distribution channels.”

Tags: , , , , ,
Posted in Consumer Staples Stocks, Health Care Stocks by admin | No Comments »


« Older Entries
Newer Entries »